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Effective therapies are urgently needed for the SARS-CoV-2/
COVID-19 pandemic. We identified panels of fully human mono-
clonal antibodies (mAbs) from large phage-displayed Fab, scFv,
and VH libraries by panning against the receptor binding domain
(RBD) of the SARS-CoV-2 spike (S) glycoprotein. A high-affinity Fab
was selected from one of the libraries and converted to a full-size
antibody, IgG1 ab1, which competed with human ACE2 for binding
to RBD. It potently neutralized replication-competent SARS-CoV-2
but not SARS-CoV, as measured by two different tissue culture
assays, as well as a replication-competent mouse ACE2-adapted
SARS-CoV-2 in BALB/c mice and native virus in hACE2-expressing
transgenic mice showing activity at the lowest tested dose of
2 mg/kg. IgG1 ab1 also exhibited high prophylactic and therapeu-
tic efficacy in a hamster model of SARS-CoV-2 infection. The mech-
anism of neutralization is by competition with ACE2 but could
involve antibody-dependent cellular cytotoxicity (ADCC) as IgG1
ab1 had ADCC activity in vitro. The ab1 sequence has a relatively
low number of somatic mutations, indicating that ab1-like anti-
bodies could be quickly elicited during natural SARS-CoV-2 infec-
tion or by RBD-based vaccines. IgG1 ab1 did not aggregate, did not
exhibit other developability liabilities, and did not bind to any of
the 5,300 human membrane-associated proteins tested. These re-
sults suggest that IgG1 ab1 has potential for therapy and prophy-
laxis of SARS-CoV-2 infections. The rapid identification (within 6 d
of availability of antigen for panning) of potent mAbs shows the
value of large antibody libraries for response to public health
threats from emerging microbes.
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The severe acute respiratory distress syndrome coronavirus 2(SARS-CoV-2) (1) has spread worldwide thus requiring safe
and effective prevention and therapy. Inactivated serum from
convalescent patients inhibited SARS-CoV-2 replication and
decreased symptom severity of newly infected patients (2), sug-
gesting that monoclonal antibodies (mAbs) could be even more
effective. Human mAbs are typically highly target specific and
relatively nontoxic. By using phage display we have previously
identified a number of potent fully human mAbs (m396, m336,
and m102.4) against emerging viruses, including severe acute
respiratory syndrome coronavirus (SARS-CoV) (3), Middle East
respiratory syndrome coronavirus (MERS-CoV) (4), and heni-
paviruses (5, 6), respectively, which are also highly effective in
animal models of infection (7–10); one of them was administered
on a compassionate basis to humans exposed to henipaviruses
and successfully evaluated in a clinical trial (11).
Size and diversity of phage-displayed libraries are critical for
rapid selection of high-affinity antibodies without the need for
additional affinity maturation. Our exceptionally potent antibody
against the MERS-CoV, m336, was directly selected from a very
large (size ∼1011 clones) library from 50 individuals (4). However,
another potent antibody, m102.4, against henipaviruses was ad-
ditionally affinity matured from its predecessor selected from a
smaller library (size ∼1010 clones) from 10 individuals (6). Thus, to
generate high-affinity and safe mAbs we used very large (size
∼1011 clones each) naive human antibody libraries in Fab, scFv, or
VH format using peripheral blood mononuclear cells (PBMCs)
from a total of 490 individuals obtained before the SARS-CoV-2
outbreak. The complementarity-determining regions (CDRs) of
the human VH domains were grafted (except CDR1 which was
mutagenized or grafted) from our other libraries as previously
described (12).
Significance
Effective therapies are urgently needed for COVID-19. We rapidly
(within a week) identified a fully humanmonoclonal germline-like
antibody (ab1) from phage-displayed libraries that potently
inhibited mouse ACE2-adapted SARS-CoV-2 replication in wild-
type BALB/c mice and native virus in transgenic mice expressing
human ACE2 as well as in hamsters when administered before
virus challenge. It was also effective when administered after vi-
rus infection of hamsters, although at lower efficacy than when
used prophylactically. Ab1 was highly specific and did not bind to
human cell membrane-associated proteins. It also exhibited good
developability properties including complete lack of aggregation.
Ab1 has potential for prophylaxis and therapy of COVID-19 alone
or in combination with other agents.
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Another important factor to consider when selecting effective
mAbs is the appropriate antigen. Similar to SARS-CoV, SARS-
CoV-2 uses the spike (S) glycoprotein to enter into host cells. The
S receptor binding domain (RBD) binds to its receptor, the human
angiotensin-converting enzyme 2 (hACE2), thus initiating a series of
events leading to virus entry into cells (13). We have previously
characterized the function of the SARS-CoV S glycoprotein and
identified its RBD which is stable in isolation (14). The RBD was
then used as an antigen to pan phage-displayed antibody libraries;
we identified potent antibodies (4, 7) more rapidly and the anti-
bodies were more potent than when we used the whole S protein or
S2 as panning antigens. In addition, the SARS-CoV RBD-based
immunogens are highly immunogenic and elicit neutralizing anti-
bodies which protect against SARS-CoV infections (15). Thus, to
identify SARS-CoV-2 mAbs, we generated two variants of the
SARS-CoV-2 RBD (amino acids [aa] 330 to 532) (SI Appendix, Fig.
S1) and used them as antigens for panning of our libraries.
Results and Discussion
Identification of High-Affinity Human Antibodies in Different Formats
Targeting the SARS-CoV-2 RBD. Panels of high-affinity binders to
RBD in Fab, scFv, and VH domain formats were identified from
our antibody phage libraries. There was no preferential use of any
antibody VH gene (an example for a panel of binders selected
from the scFv library is shown in SI Appendix, Fig. S2A) and the
number of somatic mutations was relatively low (SI Appendix, Fig.
S2B, for the same panel of binders as in SI Appendix, Fig. S2A).
The antibodies bound to SARS-CoV-2 RBD with half-maximal
effective concentrations ranging from 1 to 1,000 nM (SI Appendix,
Fig. S3A). The highest-affinity binders were converted to the IgG1
and VH-Fc fusion formats to increase binding through avidity and
half-life in vivo. Some of them including ab1, 2, 3, 9, and m398
competed to various degrees with hACE2, while others including
ab5, m399, m400, and m401 did not (SI Appendix, Fig. S3B). The
hACE2-competing antibodies ab2, 3, 9, and m398 competed with
ab1, while the hACE2-noncompeting antibodies did not compete
with ab1 for binding to RBD (SI Appendix, Fig. S3C). The m398
which competed with hACE2 relatively weakly also competed
weakly with CR3022, indicating that it has a distinct epitope
compared to the epitopes of the antibodies (ab1, 2, and 3) which
competed strongly with hACE2 (SI Appendix, Fig. S3D). None of
the antibodies cross-reacted with the SARS-CoV S1 except ab5
which exhibited weak cross-reactivity (SI Appendix, Fig. S3E). The
degree of competition with hACE2 correlated with the antibody
neutralizing activity as measured by a pseudovirus assay. IgG1 ab1
exhibited the highest degree of SARS-CoV-2 pseudovirus neu-
tralization and competition with ACE2 followed by IgG1 ab2,
while the hACE2-noncompeting antibodies did not show any
neutralizing activities (SI Appendix, Fig. S3F). Thus, IgG1 ab1 was
selected for further extensive characterization.
IgG1 ab1 Bound with High-Affinity/Avidity to the SARS-CoV-2 RBD, S1
and Cell Surface-Associated S Protein but Not to SARS-CoV S1, and
Strongly Competed with the Receptor hACE2. The Fab and IgG1
ab1 bound strongly to the SARS-CoV-2 RBD (SI Appendix, Fig.
S4A) and S1 protein (SI Appendix, Fig. S4B) as measured by
ELISA. The Fab ab1 equilibrium dissociation constant, Kd, as
measured by the biolayer interferometry technology (BLItz), was
1.5 nM (Fig. 1A). The IgG1 ab1 bound with high (160 pM) avidity
to recombinant RBD (Fig. 1B). IgG1 ab1 bound cell surface-
associated native S glycoprotein, suggesting that the conformation
of its epitope on the RBD in isolation is close to that in the native
S protein (Fig. 1C). The binding of IgG1 ab1 was of higher avidity
than that of hACE2-Fc (Fig. 1D). Binding of IgG1 ab1 was specific
for the SARS-CoV-2; it did not bind to the SARS-CoV S1 (SI
Appendix, Fig. S3E) nor to cells that do not express SARS-
CoV-2 S glycoprotein (Fig. 1C). IgG1 ab1 strongly competed
with hACE2-Fc as confirmed by the BLItz (SI Appendix, Fig.
S4C), and did not compete with the CR3022 (SI Appendix, Fig.
S4D) which cross-reacts to SARS-CoV (16) by binding to the
conserved regions in the core RBD domain distal from the re-
ceptor binding motif (RBM). The high degree of competition with
hACE2 and the lack of competition with CR3022 indicate that the
ab1 epitope is likely located in the RBM.
IgG1 ab1 Potently Neutralized Authentic SARS-CoV-2 and Induced
Antibody-Dependent Cellular Cytotoxicity (ADCC) in Tissue Cultures.
IgG1 ab1 neutralized replication-competent SARS-CoV-2 sig-
nificantly more potently (half-maximal inhibitory concentration,
IC50 = 200 ng/mL) than IgG1 ab2 and IgG1 ab3 (IC50 = 800 ng/
mL and 15 μg/mL, respectively) (Fig. 2A) as measured by a lu-
ciferase reporter gene assay. Because of possible variations be-
tween in vitro assays, the IgG1 ab1 neutralization activity was also
tested in a different laboratory by a microneutralization (MN)-
based assay, which showed similar results with a neutralization
titer to achieve 100% neutralization (NT100) at 400 ng/mL and
NT0 at 100 ng/mL (Fig. 2B). In agreement with the specificity of
binding to the SARS-CoV-2 and not to the SARS-CoV, the IgG1
ab1 did not neutralize live SARS-CoV (Fig. 2B). The IgG1 m336
(4), which is a potent neutralizer of MERS-CoV did not exhibit
any neutralizing activity against SARS-CoV-2 (Fig. 2 A and B).
The correlation between virus neutralization activity and compe-
tition with hACE2 suggests that blocking of the virus S glyco-
protein binding to the host receptor (hACE2) is the underlying
mechanism of viral neutralization as reported for many antibodies
isolated from COVID-19 patients (17–22), although some hACE2-
noncompeting antibodies including 47D11 (23) and S309 (24) also
exhibit neutralizing activity.
Importantly, IgG1 ab1 as well as an antibody, VH-Fc m401,
which does not compete with hACE2 and does not neutralize
pseudovirus (SI Appendix, Fig. S3 B and F), mediated ADCC
although at moderate levels (10 to 15% cell killing) (Fig. 2C).
Consistent with a recent finding (25), IgG1 CR3022 also medi-
ated ADCC and served as a positive control (Fig. 2C). Such
moderate levels of ADCC for IgG1s targeting the SARS-CoV-2
RBD have also been observed by others (24, 26). Antibodies with
nonoverlapping epitopes, such as ab1 and m401, mediating ef-
fector functions could be potentially combined to increase efficacy
and decrease the probability for escape mutants. ADCC as well as
other effector functions may contribute to the control of virus
infection in vivo in addition to virus neutralization but they could
also lead to greater cytopathicity (25).
IgG1 ab1 Was Highly Effective Prophylactically in Two Different
Mouse Models. To evaluate the efficacy of IgG1 ab1 in vivo we
used two mouse models of SARS-CoV-2 infection each with
unique features. The first one is based on the recently developed
mouse ACE2-adapted SARS-CoV-2 which has two mutations
Q498T/P499Y at the ACE2 binding interface on RBD and allows
the use of wild-type mice that are widely available (27). IgG1 ab1
protected mice from high titer intranasal SARS-CoV-2 challenge
(105 pfu) of BALB/c mice in a dose-dependent manner (Fig. 3A).
There was complete neutralization of infectious virus at the highest
dose of 36 mg/kg, statistically significant reduction by 100-fold at
8 mg/kg (Kruskal–Wallis test, P = 0.039), and on average 1.8-fold
decrease at 2 mg/kg. The IgG1 m336 which potently neutralizes
the MERS-CoV in vivo was used as an isotype control because it
did not have any effect in vitro. These results also suggest that the
double mutations Q498T/P499Y on RBD do not affect IgG1 ab1
binding. The second model based on transgenic mice expressing
hACE2 (28) allows the use of replication-competent virus isolated
from humans. Mice were administered 15 mg/kg of IgG1 ab1 prior
to wild-type SARS-CoV-2 challenge followed by detection of in-
fectious virus in lung tissue 2 d later. Replication-competent virus









was not detected in four of the five mice which were treated with
IgG1 ab1 (Fig. 3B). All six control mice and one of the treated
mice had more than 103 pfu per lung; the antibody probably was
not transferred to the lungs in the outlier mouse. Interestingly, in
both models about the same dose of antibody (10 to 15 mg/kg)
reduced about 100-fold the infectious virus in the lungs. This result
suggests that the evaluation of the antibody efficacy is robust in
both models and supports using the mouse-adapted virus model
for evaluation of inhibitors. The effective prophylactic dose of
IgG1 ab1 (>2 mg/kg) is in the range (10 to 50 mg/kg) of that of
other potent SARS-CoV-2 neutralizing antibodies (17, 18, 20, 21).
IgG1 ab1 Exhibited Both Prophylactic and Therapeutic Efficacy in a
Hamster Model of SARS-CoV-2 Infection. We also used the recently
developed hamster model of SARS-CoV-2 infection (29, 30) that
allowed evaluation of both prophylactic and therapeutic efficacy
of IgG1 ab1, although it requires a larger amount of antibody
than the mouse models. Intraperitoneal (i.p.) administration of
10 mg/kg IgG1 ab1 1 d before intranasal challenge of 105 50%
tissue culture infectious doses (TCID50) virus reduced infectious
virus titer in the lungs about 10,000-fold to almost undetectable
levels in four out of five hamsters at day 5 postinfection (dpi)
(Fig. 3C). The lung viral RNA was decreased by 100-fold
Fig. 1. Binding kinetics of ab1 to SARS-CoV-2 RBD and cell surface-associated S. (A) BLItz sensorgrams for Fab ab1 binding to RBD-Fc. (B) Sensorgrams for
IgG1 ab1 binding to RBD-Fc. (C) Binding of IgG1 ab1, hACE2-Fc, and IgG1 CR3022 to S transiently transfected 293T cells. The 293T cells without transfection serve
as a control. Antibodies or proteins were evaluated at concentration of 1 μM. (D) Concentration-dependent binding of IgG1 ab1 and hACE2-Fc to 293T-S cells.
Fig. 2. IgG1 ab1 potently neutralizes SARS-CoV-2 live virus measured by two different assays and mediates ADCC. (A) Neutralization of live SARS-CoV-2 by a
reporter gene assay. (B) Neutralization of live virus by a microneutralization assay. (C) ADCC activity of IgG1 ab1 and VH-Fc m401 as measured by using primary
human NK cells. The 293T cells overexpressing SARS-CoV-2 S were used as target cells. The cell death was monitored by using Promega LDH-Glo cytotoxicity assay.
The data were analyzed by the unpaired, two-tailed, Student’s t test using GraphPad Prism 7.0. A P value <0.05 was considered significant. *P < 0.05.
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(Fig. 3D), which is similar to the decrease achieved by the neu-
tralizing antibody CC12.1 (21). Importantly, i.p. administration
of IgG1 ab1 of the same dose of 10 mg/kg 6 h after viral chal-
lenge also decreased infectious virus titer (about 3,000-fold)
which is about 3-fold lower than when administered prophylac-
tically (Fig. 3C); viral RNA in the lung was also decreased about
10-fold (Fig. 3D). The antibody was administered 6 h postviral
challenge based on previous studies of SARS-CoV growth ki-
netics in VeroE6 cells showing a replication cycle of 5- to 6-h
duration (31). IgG1 ab1 also reduced lung pathology and de-
creased viral antigen in the lung (Fig. 4 A–D). Hematoxylin and
eosin (H&E) stain of lung tissues showed that IgG1 ab1 treat-
ment remarkably decreased pulmonary congestion, alveolar septal
thickening, and hyaline membrane formation caused by the
SARS-CoV-2 infection. The H&E images were scored by a
trained pathologist based on inflammation area and alveolar hem-
orrhage (clinical score 0, no microscopic lesions; 1, mild interstitial
pneumonia; 2, moderate multifocal interstitial pneumonia; 3,
moderate diffuse interstitial pneumonia; and 4, severe interstitial
pneumonia). For the IgG1 ab1 prophylactic and therapeutic
groups the clinical scores were equal to 1 and 2, respectively, and
the control one was equal to 4. In addition, the anti-SARS-CoV-2
nucleocapsid immunohistochemistry (IHC) showed a marked re-
duction of antigen-positive cells in IgG1 ab1 prophylactic and
therapeutic treatment groups compared to the control groups
(Fig. 5A).
IgG1 ab1 not only decreased viral burden in the hamster lung,
but also reduced viral shedding in hamster nasal washes and oral
swabs (Fig. 5 B, C, E, and F). In control hamsters (infected but
not treated), viral load in nasal washes was higher than that in
oral swabs, and viral shedding waned faster in oral swabs, which
may relate to the relatively high ACE2 expression in nasal epi-
thelial cells and emphasizes the roles of the nasal epithelium in
the initial viral infection and transmission (32). Both IgG1 ab1
prophylactic and therapeutic treatment decreased viral RNA and
infectious viral titers in nasal washes and oral swabs at 3 and 5
dpi except viral RNA in the nasal washes, which was not de-
creased in the therapeutic group. The viral reduction at 1 dpi was
not as significant as that at 3 and 5 dpi, likely due to the infection
peak occurring before day 3 as reported in hamsters (33). The
prophylactic treatment decreased viral loads more effectively
than the therapeutic treatment. Overall, the viral RNA decrease
in hamster shedding was not as obvious as the decrease observed
in the lung tissue, consistent with a recent finding in hamsters
(30). The decreased viral shedding in the upper airways could
potentially reduce transmission of SARS-CoV-2. Here we report
the results of a human mAb tested prophylactically in three dif-
ferent animal models, suggesting approximate equivalency of
those models in terms of antibody efficacy evaluation.
Fig. 3. IgG1 ab1 potently neutralizes SARS-CoV-2 in three animal models. (A) IgG1 ab1 inhibits mouse ACE2-adapted SARS-CoV-2 in wild-type BALB/c mice.
Mice were treated i.p. with varying doses of IgG1 ab1 or an isotype control 12 h prior to intranasal infection with 105 pfu of mouse-adapted SARS-CoV-2. Lung
tissue was homogenized in PBS and virus replication assessed by plaque assay using VeroE6 cells (Kruskal–Wallis test followed by Dunn’s test, ns: P > 0.05, *P <
0.05, ***P < 0.001). (B) IgG1 ab1 protects hACE2 transgenic mice from SARS-CoV-2 infection. The experimental protocol is similar to the one above except that
human ACE2 transgenic mice and wild type SARS-CoV-2 were used (Mann–Whitney U test, *P < 0.05). (C and D) Evaluation of prophylactic and therapeutic
efficacy of IgG1 ab1 in a hamster model of SARS-CoV-2 infection. IgG1 ab1 significantly reduced the lung viral titers (C) and viral RNA presented as TCID50
equivalents (D). Hamsters were injected intraperitoneally with 10 mg/kg of IgG1 ab1 antibody either 1 d before (prophylaxis) or 6 h after (therapy) intranasal
challenge of 1 × 105 TCID50 of SARS-CoV-2. At the time of killing (5 dpi), lungs were collected for virus titration by viral TCID50 assays and viral RNA quan-
tification by RT-qPCR (Kruskal–Wallis test followed by Dunn’s test, *P < 0.05, **P < 0.01).









Our results suggest that IgG1 ab1 can suppress the spread of
newly produced virus in vivo, although the efficacy was lower
compared to the prophylactic administration. Lower efficacy of
therapy compared to prophylaxis was also observed for two other
anti-SARS-CoV-2 antibodies (17, 20). One possible reason for
the lower efficacy could be the larger amount of infectious virus
produced in the animal after the first cycle(s) of replication and
possibility for cell-to-cell spread. Another related contributing
factor could be the decreased antibody concentration due to for-
mation and removal of antigen/antibody complexes as we previ-
ously showed for HIV-1 (34). Indeed, the IgG1 ab1 concentration
in the therapeutic group (20 to 30 μg/mL at day 1 and 0 to 15 μg/
mL at day 5 after challenge) was significantly lower than that in
the prophylactic group (30 to 50 μg/mL and 15 to 30 μg/mL, re-
spectively) (Fig. 5D). Similar concentrations were reported for the
neutralizing antibody CC12.1 (21). The IgG1 ab1 concentration in
sera needed for protection was much higher (∼250-fold) than the
in vitro live virus IC50 which is generally observed for many anti-
viral antibodies (35). The relatively high concentration of IgG1
ab1 6 d after administration also indicates good pharmacokinetics.
IgG1 ab1 Has Relatively Low Levels of Somatic Hypermutations and
Good Developability. Interestingly, Fab ab1 had only several so-
matic mutations compared to the closest germline predecessor
genes, which was also observed for many neutralizing antibodies
from COVID-19 patients (36–38). We and others have demon-
strated that germline-like antibodies can also be highly effective
against other viruses causing acute infections such as henipaviruses
(5, 6), SARS-CoV (7), MERS-CoV (39), influenza (40), Dengue
virus (41) and Zika virus (42); they can be rapidly elicited through
an “innate-like” antiviral recognition mediated by antigen-specific
naive B cell receptors in a germinal center-independent manner
(43). The low number of somatic hypermutations of ab1 implies
that ab1-like antibodies could be elicited relatively quickly by using
RBD-based immunogens especially in some individuals with naive
mature B cells expressing the germline predecessors of ab1. This is
in contrast to the highly mutated broadly neutralizing HIV-1 an-
tibodies that require long maturation times, are difficult to elicit,
and their germline predecessors cannot bind native HIV-1 enve-
lope glycoproteins (44, 45). The germline-like nature of the newly
identified mAb ab1 also indicates that it has excellent develop-
ability properties that could accelerate its development for pro-
phylaxis and therapy of SARS-CoV-2 infection (46).
To further assess the developability (druggability) of ab1, its
sequence was analyzed online (http://opig.stats.ox.ac.uk/webapps/
newsabdab/sabpred/tap); no obvious liabilities were found. In
addition, we used dynamic light scattering (DLS) and size exclu-
sion chromatography (SEC) to evaluate its propensity for aggre-
gation. IgG1 ab1 at a concentration of 2 mg/mL did not aggregate
after 6 days of incubation at 37 °C as measured by DLS (SI Ap-
pendix, Fig. S5A); there were no high molecular weight species in
freshly prepared IgG1 ab1 also as measured by SEC (SI Appendix,
Fig. S5B). IgG1 ab1 also did not bind to the human cell line 293T
(Fig. 1C) even at very high concentration (1 μM) which is about
660-fold higher than its Kd, indicating absence of nonspecific
binding to many membrane-associated human proteins. The IgG1
ab1 also did not bind to 5,300 human membrane-associated pro-
teins as measured by a membrane proteome array (SI Appendix,
Fig. S5C).
Conclusion
The high affinity/avidity and specificity of IgG1 ab1 along with
potent neutralization of virus and good developability properties
suggest its potential use for prophylaxis and therapy of SARS-
CoV-2 infection. Because it strongly competes with hACE2 in-
dicating a certain degree of mimicry, one can speculate that
mutations in the RBD that decrease ab1 binding may also lead to
inefficient entry into cells and infection. However, in the unlikely
Fig. 4. Histopathology (H&E) and IHC of hamster lung tissue. (A and B) Treatment with IgG1 ab1 reduces pathological changes in lung tissue. H&E-stained
sections of lungs were compared between untreated hamsters (control), IgG1 ab1 prophylactically treated hamsters (A), and therapeutically treated hamsters
(B). Images represent pathological changes in lung tissues. Arrows show the inflammatory cell infiltration with alveolar hemorrhage. (C and D) IHC for
detection of SARS-CoV2 nucleocapsid antigen with anti-nucleocapsid rabbit polyclonal antibodies followed by the horseradish peroxidase (HRP)-conjugated
anti-rabbit antibody. A granular, multifocal distribution is noted in lung tissue background from control animals while prophylactic treatment with IgG1 ab1
resulted in a marked reduction in the distribution of antigen-positive cells. Arrow indicates nucleocapsid-positive cells (brown) in lungs at day 5 postinfection.
(D) The lung IHC for IgG1 ab1 therapeutically treated hamsters compared to those of controls.
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case of such mutations, ab1 can be used in combination with other
mAbs with distinct epitopes including those we identified here or
in bi(multi)specific formats. Ab1 could also be used to select ap-
propriate epitopes for vaccine immunogens and for diagnosis of
SARS-CoV-2 infections. The identification of neutralizing mAbs
within days of target availability shows the potential value of large
antibody libraries for rapid response to emerging viruses.
Methods
Generation of SARS-CoV-2 RBD, Panning of Phage Libraries, and Screening by
ELISA and BLItz. SARS-CoV-2 RBD-his and Fc, S1-Fc, ACE2-Fc, CR3022 Fab, and
IgG1 were subcloned into pcDNA3.1. Proteins were expressed with the
Expi293 expression system and purified with protein A resin or by Ni-NTA resin.
The recombinant RBD proteins was used to pan our naive human antibody
phage display libraries, which were made based on the antibody cDNA from a
total of 490 healthy donors’ PBMCs and splenocytes. These libraries contain
very large transformants (size for each ∼1011) and are highly diverse. Bio-
panning was based on the pull-down method by using streptavidin-M280
Dynabeads. After panning, positive binders were selected by phage ELISA.
Their binding was subsequently measured by RBD binding ELISA, hACE2
competition ELISA, and the binding kinetics were measured by the biolayer
interferometry technology (BLItz). The leading candidates were converted to
the IgG1 or VH-Fc fusion formats.
Neutralization of Pseudotyped and Replication-Competent SARS-CoV-2 and In
Vitro ADCC Assay. The pseudovirus neutralization assay was based on the
SARS-CoV-2 S pseudotyped HIV-1 virus (with luciferase in the genome) entry
into hACE2-expressing cells. For testing neutralization against live SARS-
CoV-2, we used two independent assays. The first one is the standard
live virus-based MN assay based on the microscopic observation of virus-
induced formation of cytopathic effect. The other one is based on the full-
length viruses expressing luciferase, which were designed and recovered
via reverse genetics and described previously (47). For the ADCC assay,
human natural killer (NK) cells from healthy donors were isolated from
PBMCs. The 293T cells stably expressing SARS-CoV-2 S (293T-S) were used
as target cells. Cell death was evaluated by using the LDH-Glo cytotoxicity
assay.
Evaluation of IgG1 ab1 Prophylactic and Therapeutic Efficacy in Three Animal
Models. For the inhibition of mouse-adapted SARS-CoV-2 in wild-type mice, a
recombinant mouse ACE2-adapted SARS-CoV-2 virus was constructed (27).
Groups of 5 each of 10- to 12-mo-old female BALB/c mice were treated
prophylactically (12 h before 105 pfu intranasal infection) intraperitoneally
with doses of 36, 8, and 2 mg/kg. Two days postinfection, mice were killed,
and lung viral titer was determined by plaque assay. For the evaluation of
IgG1 ab1 efficacy in the hACE2 mouse model, hACE2 transgenic 6- to
9-wk-old C3B6 mice were treated intraperitoneally with 0.3 mg (15 mg/kg)
of antibody (five mice) or negative controls (six mice) 15 h prior to intranasal
infection with 105 pfu of wild-type SARS-CoV-2. Lung tissue was homoge-
nized in phosphate-buffered saline (PBS) and virus replication assessed by
plaque assay on VeroE6 cells. In the hamster model of SARS-CoV-2 infection, all
hamsters (n = 5) were injected intraperitoneally with 10 mg/kg of IgG1 ab1
antibody either 24 h prior to (prophylaxis) or 6 h after (therapy) intranasal
challenge of 1 × 105 TCID50 of SARS-CoV-2. Untreated hamsters were kept
as a control. Nasal washes and oral swabs were collected at days 1, 3, and 5
postinfection. Hamsters were bled at 1 and 5 dpi. All hamsters were killed
on 5 dpi. At the time of killing, lungs were collected for virus titration and
RNA isolation. For testing sera IgG1 ab1 concentrations, SARS-CoV-2 spike-
1 (S1) ELISA was used. For histopathology on day 5 postinfection, 10%
formalin-fixed and paraffin-embedded tissues were processed with either
H&E or IHC for detection of SARS-CoV2 nucleocapsid antigen. Lung lobe
H&E-stained images were scored based on pathology using microscopy.
IHC was quantified using ImageJ software by counting positive cells at 40×
magnification.
Detailedmaterials andmethods for this study are described in SI Appendix.
Ethics Statement.HumanACE2 transgenic C3B6mice (6 to 9wk old) and BALB/
c mice (10 to 12 wk old) were used for all experiments. The study was carried
Fig. 5. Quantification of IHC, measurement of IgG1 ab1 concentration in hamster sera postvirus challenge, and detection of infectious virus and viral RNA in
hamster shedding including nasal washes and oral swabs. (A) Quantification of IHC image. IHC was quantified using ImageJ software by counting positive cells
at 40× magnification (unpaired, two-tailed Student’s t test. **P < 0.01, ***P < 0.001). (B, C, E, and F) Detection of infectious virus and viral RNA in hamster
nasal washes and oral swabs. Nasal washes and oral swabs were collected at day 1, 3, and 5 postinfection (dpi) for virus titer titration by TCID50 assays and viral
RNA quantification by RT-qPCR. (B and E) Nasal washes viral RNA and viral titer in untreated, pretreated, and posttreated hamsters (Kruskal–Wallis followed
by Dunn’s test, ns: P > 0.05, *P < 0.05, **P < 0.01). (C and F) Oral swab viral RNA and viral titer in untreated, pretreated, and posttreated hamsters
(Kruskal–Wallis followed by Dunn’s test, ns: P > 0.05, *P < 0.05, **P < 0.01). (D) IgG1 ab1 concentration in hamster sera when administered prophylactically
and therapeutically. Hamsters were bled at 1 and 5 dpi for measuring antibody concentrations in sera by SARS-CoV-2 S1 ELISA (two-way ANOVA followed by
Tukey’s test, ns: P > 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001).









out in accordance with the recommendations for care and use of animals by
the Office of Laboratory Animal Welfare, National Institutes of Health, and
the Institutional Animal Care and Use Committee of the University of North
Carolina (UNC permit no. A-3410-01). For the hamster model, studies were
approved by the University Animal Care Committee of the University of
Saskatchewan according to the guidelines of the Canadian Council on
Animal Care.
Statistical Analyses. Statistics of the ADCC and IHC quantification data were
determined by the unpaired, two-tailed, Student’s t test using GraphPad
Prism 7.0; *P < 0.05, **P < 0.01, ***P < 0.001. The hACE2 transgenic mouse
data were analyzed by the Mann–Whitney U test; *P < 0.05. The signifi-
cances for the mouse ACE2-adapted model and viral titer, viral RNA in
hamsters lung, nasal washes, and oral swabs were determined by the
Kruskal–Wallis test followed by Dunn’s test; ns: P > 0.05, *P < 0.05, **P <
0.01, ***P < 0.001. The significance of IgG1 ab1 concentration in hamster
sera was determined by the two-way ANOVA analysis followed by Tukey’s
test; ns: P > 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Data Availability. All data supporting the findings of this study are included in
the main text and SI Appendix; physical materials will be made available
upon request after completion of a Material Transfer Agreement. Antibody
variable domain sequences were deposited to GenBank with accession numbers
MW118116 and MW118117 and are only allowed for noncommercial use.
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